RxDoctor Payments Data

James Palen, MD

Family Medicine · Cape Girardeau, MONPI 1598902728

Payments from drug & device makers

$9,568in general payments, 2019–2025

Across 561 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$950
  • Novo Nordisk$585
  • Lilly USA, LLC$541
  • Johnson & Johnson$505
  • Amgen$417
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$9,47499%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)109$1,820
AstraZeneca53$950
Novo Nordisk41$585
Lilly USA, LLC33$541
Johnson & Johnson28$505
Amgen24$417
Astellas Pharma US Inc18$376
Pfizer16$275
Otsuka America Pharmaceutical, Inc.13$266
Amarin Pharma, Inc.15$246
Lundbeck LLC13$232
Merck14$219
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$196
Nestle Healthcare Nutrition Inc.9$177
Takeda Pharmaceuticals U.S.A., Inc.10$167
Axsome Therapeutics, Inc.7$158
GSK10$153
Scilex Pharmaceuticals Inc.9$150
Sanofi-aventis U.S. LLC8$141
Biohaven Pharmaceutical Holding Company Ltd.7$129
Bayer8$125
Xeris Pharmaceuticals, Inc.5$113
Novartis7$112
Mylan Specialty L.p.6$112
Boehringer Ingelheim6$94
Exact Sciences5$87
Avanir Pharmaceuticals, Inc.6$80
Eisai Inc.4$76
E.r. Squibb & Sons, L.L.C.5$73
Phathom Pharmaceuticals, Inc.4$68
Viatris Specialty LLC4$65
Paratek Pharmaceuticals, Inc.4$62
Vanda Pharmaceuticals Inc.2$60
Teva Pharmaceuticals USA, Inc.4$59
Idorsia Pharmaceuticals US Inc4$59
Upsher-smith Laboratories LLC3$54
Verona Pharma, Inc.3$53
Abbott2$48
Sumitomo Pharma America, Inc.3$46
Aimmune Therapeutics, Inc.2$38
Ardelyx, Inc.2$36
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$35
Biohaven Pharmaceuticals, Inc.2$34
Daiichi Sankyo Inc.2$31
Averitas Pharma Inc.1$28
Seqirus USA Inc1$27
Arbor Pharmaceuticals, Inc.2$26
Electromed, Inc.2$25
SK Life Science, Inc.1$21
Supernus Pharmaceuticals, Inc.1$20
Apria Healthcare LLC1$17
Valinor Pharma, LLC1$15
Adlon Therapeutics L.p.1$14
Kowa Pharmaceuticals America, Inc.1$14
Neurocrine Biosciences, Inc.1$13
Neos Therapeutics, LP1$13
Almatica Pharma LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,568 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$357,787
Medicare patients
450
Services billed
5,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$134,613
MounjaroTirzepatide111$130,213
OzempicSemaglutide96$103,447
AustedoDeutetrabenazine24$92,619
XareltoRivaroxaban229$76,534
FarxigaDapagliflozin Propanediol167$75,454
TrulicityDulaglutide80$71,660
XifaxanRifaximin21$69,397
LinzessLinaclotide124$68,652
Droxidopa14$62,640
JardianceEmpagliflozin115$53,000
MyrbetriqMirabegron149$48,082
TradjentaLinagliptin116$43,244
JanuviaSitagliptin Phosphate51$36,146
VraylarCariprazine Hcl44$34,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$541$201,873191 claims
AbbVieLinzess, Vraylar, Creon, Qulipta$1,820$149,957221 claims
PfizerEliquis$275$134,613349 claims
Novo NordiskOzempic, Rybelsus$585$115,755108 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$94$105,220249 claims
AstraZenecaFarxiga, Breztri Aerosphere$950$101,575207 claims
Teva Pharmaceuticals USA, Inc.Austedo$59$92,61924 claims
Johnson & JohnsonXarelto$505$76,534229 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$196$69,39721 claims
Astellas Pharma US IncMyrbetriq$376$48,082149 claims
MerckJanuvia, Belsomra$219$46,41471 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$153$41,79779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →